CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 85 enrolled
Drug / intervention
Sitagliptindrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01610154
NCT01610154Phase 4Completed
CompareCT.gov

Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

Guangwei Li·interventional·Posted Jun 1, 2012·Updated May 11, 2017

In Brief

A Phase 4 clinical trial evaluating Sitagliptin for Insulin Secretion and Insulin Resistance. Completed, enrolled 85 participants across 1 site.

Detailed Summary

1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2. There are different effects of Sitagliptin therapy on blood glucose regulation, pancreatic alpha \& beta cell function are different in lean (BMI\<25) and overweight (BMI\>25) Chinese type 2 diabetics. 3. The purpose of this study is to determine whether glucagon release may contribute over 30% to the hyperglycemia in Chinese type 2 diabetics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsulin Secretion, Insulin Resistance
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 1, 2012
Enrollment StartOct 1, 2012
Primary CompletionAug 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.1 years ago

Interventions

Sitagliptindrug

Sitagliptin 100 mg QD for 12 weeks